Ablexis' AlivaMab Mouse platform will fill critical unmet commercial needs in therapeutic antibody discovery. Recent changes in the landscape of providers in this space have diminished the availability of transgenic mouse platforms highly sought by experienced discoverers of human therapeutics antibodies. By leveraging new insights in the understanding of immune responses, advances in antibody drug discovery and development, and innovative genetic engineering methods, we will improve upon existing platform technologies. These new insights combined with the significant experience of our team support the development of the AlivaMab Mouse technology, an efficient, innovative, next-generation transgenic mouse platform for antibody drug discovery.
